MGX

Price & events

Pipeline · 0 trials · 0 upcoming

Catalyst news & presentations · 12

• 2027Guided 40%trial initiationsecondaryPhase 1MGX-001 · First-in-human study initiationSEC 8-K
• 2026Guided 40%trial initiationsecondaryNominate DC for lead secreted protein deficiency.SEC 8-K
• 4Q 2026Guided 70%regulatory submissionFiled (NDA/BLA)MGX-001 · IND/CTA submissions for MGX-001 hemophilia A programSEC 8-K
• 2025-12-31fda agreementMGX-001 · Pre-IND meeting completed for MGX-001 in Q4 2025SEC 8-K
• 2025readoutDemonstrate NHP proof-of-concept for lead secreted protein deficiency target.SEC 8-K
• 2025filing acceptanceFiled (NDA/BLA)Pre-IND and ex-US regulatory meetings.SEC 8-K
• 2025readoutlead secreted protein target · NHP proof-of-concept data for lead secreted protein deficiency targetSEC 8-K
• 2025trial initiationsecondaryNominate one to two DCs from four Wave 1 Ionis programs and disclose remaining indications.SEC 8-K
• first half of 2025readoutMGX-001 · Release final FVIII durability and related preclinical study data from NHP durability study.SEC 8-K
• Thursday, May 22, 2025, 2:30 p.m. PTconferencedata presentationsecondaryAI-guided metagenomic discovery of compact CRISPR systems at TIDES USA 2025SEC 8-K
• May 13-17, 2025conferencedata presentationsecondaryMG21-1, MG119-28, Type V-K CAST · Three abstracts presented at ASGCT 2025 showcasing compact nucleases for CNS editing and CAST for large gene integration.SEC 8-K
• Tuesday, May 13, 2025, 6:00 p.m. CTconferencedata presentationsecondaryPresentations on gene editing technologies at ASGCT 28th Annual MeetingSEC 8-K